Trial Profile
Randomized, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses or Multiple Ascending Doses of OSCN-, bLF or ALX-009 in Healthy Male and CF and Non-CF Bronchiectasis Patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Bovine lactoferrin (Primary) ; Bovine lactoferrin/hypothiocyanite (Primary) ; Hypothiocyanite (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors Alaxia
- 20 Jan 2022 Status changed from recruiting to discontinued. Reason the study was stopped: Financial issues
- 16 Apr 2021 Planned End Date changed from 1 Feb 2020 to 1 Oct 2021.
- 16 Apr 2021 Planned primary completion date changed from 1 Feb 2020 to 1 Oct 2021.